allylestrenol and Hypogonadism

The effect of estradiol valerate and allylestrenol on the endometrial transformation of five hypergonadotropic hypogonadic women was evaluated. Estradiol valerate was administered throughout the whole induced cycle (28 days), while allylestrenol was added during the second half of the cycle. Endometrial biopsies were performed during allylestrenol treatment and were evaluated histologically. Samples of endometrium were also subjected to one-dimensional SDS electrophoresis. Of ten biopsies performed, only one was interpreted to be in-phase, while the others were dated proliferative (4 biopsies) or showed abortive or out-of-phase secretory transformation. The highest mean serum progesterone level, detected under allylestrenol treatment, was 1.5 ng/ml. Protein electrophoresis demonstrated relative sequential changes in the protein patterns of the 115 kDa and 150 kDa protein bands. It is concluded that allylestrenol, although having gestagen properties, may not be efficient for the induction of an adequate secretory transformation of human endometrium in the absence of ovaries.

Topics: Adult; Allylestrenol; Biopsy; Drug Therapy, Combination; Endometrium; Estradiol; Estrenes; Female; Gonadotropins, Pituitary; Humans; Hypogonadism; Menopause, Premature; Ovariectomy; Postoperative Complications; Progesterone

Topics: Abortion, Threatened; Adrenal Hyperplasia, Congenital; Allylestrenol; Drug Evaluation; Drug Therapy, Combination; Ethinyl Estradiol; Female; Humans; Hypogonadism; Prednisolone; Pregnancy